Tissue Regenix Share Discussion Threads

[alphapig] 07/12/2017 14:23

Low volume on show for such a drastic fall, have to wait for delayed trades. How they off for cash?

[alphapig] 07/12/2017 11:23

Today's trades wiped off another £6 mil of the market cap, utter shambles.

[channel pirate] 07/12/2017 11:13

Not sure what to make of this here now as the share price continues to slide.

Recently the company stated "Current trading remains in line with Board expectations." Might be good to tell us shareholders just what their expectations are !!

[multibagger] 29/11/2017 18:34

Rather than regenerative medicine - TRX should focus on creating a generative investment and returns for shareholders :)

[brynorite] 29/11/2017 18:22

People need to sit tight, this is a company that will do well, its not about instant profits. This will be a market leader but patience is required.

[rayrac] 29/11/2017 08:26

I sold out some time ago, at a higher price than todays I might add. But is Woodford about to take another hit? A small one perhaps, but nevertheless not good for his fund!
I’m thinking he was restrained in his investment ideas at his previous employment and now wishes he had stayed there?

[channel pirate] 15/11/2017 12:40

Well a 29,150,000 trade at mid price - that should get us a "Holdings" RNS for sure !!

Over a week gone by and no "Holdings RNS", so maybe not one of the existing "big boys", therefore can only think it might be the new American Director loading up with a few and not reached a 3% holding yet.

[grahamburn] 10/11/2017 14:48

Well done for the contact, but, in all honesty, not especially enlightening in terms of the "how".

Let's wait and see some genuinely detailed statements of that.

[channel pirate] 10/11/2017 09:45

Sent an Email to Mr Couldwell (new CEO)and have received a reply, (I feel sure he would not mind me sharing with you all) - see both below
Never ever got a reply to emails sent to the company with previous CEO in place !!

03rd November 2017.

Dear Mr Couldwell,
Congratulations on your appointment of C.E.O. of Tissue Regenix Group plc
I look forward to you using your past experience etc in building / guiding the company into a very successful player in the regenerative medical arena as you grow it’s potential.
Wishing you every success.
Kind Regards,
XYZ (shareholder)
...................................................................................

10th November 2017

Dear Mr XYZ, many thanks for your email forwarded to me via Caitlin.

I’m excited by the opportunities we have at TRG and look forward to leading the organization to increasing commercial and value creation success

Kind Regards
Steve Couldwell

[bamboo2] 06/11/2017 09:16

Igbert, lol. I didn't think trx would join the ranks of aim penny shares.

Something newswise had better happen pretty quickly.

[igbertsponk] 02/11/2017 07:16

Buggins turn

[channel pirate] 02/11/2017 07:10

02/11/2017 7:00am

UK Regulatory (RNS & others)



Tissue Regenix (LSE:TRX)
Intraday Stock Chart

Today : Thursday 2 November 2017
Click Here for more Tissue Regenix Charts.
TIDMTRX

RNS Number : 3338V

Tissue Regenix Group PLC

02 November 2017

Tissue Regenix Group plc

Appointment of CEO

Steve Couldwell appointed Group CEO

Leeds, 02 November 2017 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces the appointment of Steve Couldwell, as Chief Executive Officer of the Group, effective immediately. Steve has been in the position of non- executive director since July 2013.

Steve has over 25 years' experience in the pharmaceutical and medical device industry and a proven track record of delivering revenue and profit growth. Most recently Steve was Chief Operating Officer - Global Sanofi Biosurgery, with responsibility for strategy and execution for global business including manufacturing, regulatory, medical affairs and marketing/ commercial execution, delivering strong double digit growth internationally for 3 consecutive years. Prior to this Steve held a number of roles at Smith & Nephew including President, Orthopaedics, Europe and Senior VP Sales and Marketing of the Advanced Wound Management business.

Steve Couldwell, Tissue Regenix incoming CEO commented: "Since being appointed to the board in 2013 I have been impressed with the great commercial potential of our dCELL platform. The recent acquisition of CellRight Technologies has increased the market potential and provided a highly complementary product range in the $1.7bn[1] US bone graft and substitute market. I am delighted to be appointed CEO and look

forward to leading the Group through the integration of CellRight and expansion of commercial activities as we execute our commercial strategy and grow our market share throughout the US and the rest of the world."

John Samuel, Chairman, Tissue Regenix: "The Board and I are delighted to welcome Steve as the Group's new CEO. He has an exceptional track record of growing businesses and the Board firmly believes that Steve has the required skillset and experience to guide the Group along the pathway to profitability. Alongside this, Steve has an in-depth knowledge of the Group thanks to his years as a non-executive director making him an ideal candidate for this position."

Additional information on Mr Couldwell

The following additional information is provided in accordance with paragraph (g) of Schedule Two to the AIM Rules for Companies:

Current and past Directorships and Partnerships for Steve Couldwell within the last 5 years, aged 57:

Current

-- Tissue Regenix Group plc
-- Zilico

There is no further information required to be disclosed pursuant to Schedule 2(g) of the AIM Rules.

For more Information:

[swiss paul] 31/10/2017 18:48

Any news on appointment yet

[channel pirate] 28/10/2017 19:47

From the RNS 20th July 2017...............
............Tissue Regenix also announces its intention to raise gross proceeds of approximately GBP40 million pursuant to a placing of up to 400 million new Ordinary Shares less the number of any Subscription Shares (as defined below) (the "Placing Shares") in the Company at a price of 10 pence per Placing Share, with both new and existing institutional investors (the "Placing").

I wonder how those "new and existing institutional investors" are feeling with their discounted privileged investments now, seeing Mr Small pi buying as low as 8.15p on Friday just gone ?

[ali47fish] 27/10/2017 16:29

where is everyone when the share price 8pc down?

[rayrac] 18/10/2017 13:41

So Odell won’t be at the presentation then. Wonder who will? Some mighty tough questions for whoever it is!

Urrm, why are you doing this? I don’t know...Woodford said he had to go..and go he did...

[igbertsponk] 18/10/2017 11:25

Just got this, think it may change!

"Good morning,

You are warmly invited to attend Proactive Investors' One2One Healthcare Forum which is taking place on Thursday 2nd November at The Chesterfield Mayfair Hotel from 6pm. Presenting on the evening will be ImmuPharma (LON:IMM), Widecells (LON:WDC), Synairgen (LON:SDX) & Tissue Regenix (LON:TRX).

To register to attend please click on the panel to the right or reply to this email.

ImmuPharma (LON:IMM - Market Cap: £131 Million)
...

Widecells (LON:WDC Market Cap: £9 Million)

....

Tissue Regenix (LON:TRX - Market Cap: £106 Million)

Tissue Regenix is a leading medical devices in the field of regenerative medicine. The company's patented dCELL technology removes DNA and other cellular material from animal and human soft tissue leaving a cellular tissue scaffold.

Current applications address many critical clinical needs such as sport medicine, heart valve replacement and wound care.

CEO Anthony Odell will be at the forum to present to investors and answer any questions on the company.

[channel pirate] 18/10/2017 10:04

Well at the moment it looks like the market hasn't seen the departure of Antony Odell as a big negative as the share price hasn't moved - and to buy is only 0.068 of a penny cheaper than yesterday.

(delayed reaction !! so now they bring the share price down later in the morning / afternoon)

[rayrac] 18/10/2017 08:38

Well, it obviously isnt a health issue for the departing ceo! All seems rather strange to me, perhaps Woodford wasn't keen on the performance and wanted him out?

Whatever, it smells!

[igbertsponk] 18/10/2017 07:16

Yes, time some new blood given a go.

[channel pirate] 18/10/2017 07:13

18/10/2017 7:00am

UK Regulatory (RNS & others)

Tissue Regenix (LSE:TRX)
Intraday Stock Chart

Today : Wednesday 18 October 2017
Click Here for more Tissue Regenix Charts.
TIDMTRX

RNS Number : 8786T

Tissue Regenix Group PLC

18 October 2017

[This announcement contains inside information.]

Tissue Regenix Group plc

Directorate Change

Leeds, 18 October 2017 - The Board of Tissue Regenix Group plc (AIM:TRX) ("Tissue Regenix" or "The Group") today announces that Antony Odell, Chief Executive Officer (CEO), will be stepping down from his role and position on the Board with immediate effect. The Board will commence a process for appointment of a new CEO. In the interim, John Samuel, Non- Executive Chairman has assumed the role of Executive Chairman.

John Samuel, Executive Chairman Tissue Regenix Group, commented: "The Board of Directors and I would like to thank Antony for his dedication and commitment to Tissue Regenix since he was appointed CEO in 2008. He has been a key member of the executive team. During his tenure the Company has listed on the AIM market, successfully commercialised products in the US and earlier this year completed the transformational acquisition of CellRight, while continuing to pursue additional commercial opportunities. We wish him every success in his future career."

The integration of CellRight continues as planned and current trading remains in line with Board expectations.

[andrewbaker] 13/10/2017 12:07

The product is great (in theory, as I have no practical knowledge) yet the company is not, it seems. These small spin-off businesses are speculative buys as there are so many factors that determine their success, not just the product. I'm long, and have been for a while, and I'm going to watch closely for a sign either way: if we're not above 15p by the New Year, then I'll reduce, as I will if we drop under 10p. Maybe Warren had better rephrase his remark about companies run by monkeys, and replace the animal with pigs, in this case. Trouble is, this business needs better management, IMHO.

[alphapig] 11/10/2017 14:30

That's about 1.4 mil shares dumped at 10.5 over the last few days, not awe inspiring.